This page shows the latest daclatasvir news and features for those working in and with pharma, biotech and healthcare.
Other NS5A inhibitors on the market for HCV include Gilead's ledipasvir, Bristol-Myers Squibb's daclatasvir, AbbVie's dasabuvir and Merck &Co's elbasvir.
It also worked in patients who had failed earlier treatments that included NS5A inhibitor drugs such as Gilead's ledipasvir and velpatasvir, Bristol-Myers Squibb's daclatasvir, AbbVie's dasabuvir and
NICE issued positive final draft guidance for Gilead's Harvoni (sofosbuvir/ledipasvir), BMS' Daklinza (daclatasvir) and AbbVie's Viekirax (ombitasvir/paritaprevir/ritonavir), with or without Exviera (dasabuvir), making the new drugs
Drugs such as AbbVie's Exviera (dasabuvir), Johnson &Johnson's Olysio (simprevir), Gilead's Sovaldi (sofosbuvir) and Bristol-Myers Squibb's Daklinza (daclatasvir) have essentially revolutionised treatment, but the latter two
As World Hepatitis Day draws to a close, Bristol-Myers Squibb has hit back at NICE's decision to restrict use of its new hepatitis C treatment Daklinza (daclatasvir) to a
Hepatitis C. Finally, Bristol-Myers Squibb's hepatitis C drug Daklinza (daclatasvir) has been approved by the FDA as a combination treatment with Gilead's blockbuster pill Sovaldi (sofosbuvir) to treat
More from news
Approximately 7 fully matching, plus 32 partially matching documents found.
We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...